Welcome to the new Gustave Roussy website
A new website designed to offer you a simpler, clearer, and more intuitive experience. Patients, caregivers, healthcare professionals, and donors: find information, news, and services more easily.
Sofinnova Partners and Gustave Roussy launch first biotech company through Strategic Partnership
On
PARIS, France – March 18, 2025
Sofinnova Partners and Gustave Roussy launch first biotech company through Strategic Partnership
Signadori Bio, a novel cell therapy platform, emerges from collaboration with scientific founders Dr. Jean-Luc Perfettini and Professor Nathalie Chaput
Sofinnova Partners, a leading European life sciences venture capital firm, in collaboration with Gustave Roussy, Europe’s leading cancer center, announces the creation of their first pioneering biotech company.
Signadori Bio, developed with scientific founders Dr. Jean-Luc Perfettini and Professor Nathalie Chaput, is a breakthrough cell therapy platform focused on transforming cancer treatment. This milestone marks a significant achievement in their strategic partnership, aimed at accelerating biotech innovation through rigorous evaluation and development of scientific research.
Since the partnership's inception in 2023, it has rigorously evaluated 50 promising projects. This has culminated in the creation of a groundbreaking biotech venture in the cell and gene space that is set to advance innovative approaches in oncology. More information will be released as the company comes out of stealth later this year. Additionally, several other promising projects are in the pipeline, showcasing the immense potential for future breakthroughs in cancer therapeutics.
“With cancer on the rise, particularly among younger populations, it’s critical that we fast-track the most promising scientific breakthroughs into tomorrow’s treatments. This partnership is a powerful example of how academia and investors can work together to drive innovation through new companies,” said Professor Fabrice Barlesi, General Director of Gustave Roussy. “Gustave Roussy is at the forefront of cancer discovery. With Sofinnova’s expertise in company creation, we are now able to quickly translate these innovations into real-world therapies to benefit patients worldwide.”
Matthieu Coutet, Partner at Sofinnova Partners and CEO of Signadori Bio, added: “Turning cutting-edge research into biotech success stories requires more than financing or scientific excellence—it demands the right ecosystem. By combining Gustave Roussy’s research power with Sofinnova’s proven ability to build and scale biotech ventures, we’re creating a direct path from lab to the clinic.”
As these ventures progress, Sofinnova Partners and its academic collaborators remain committed to fostering the next generation of biotech companies and driving innovation in cancer therapeutics. This groundbreaking initiative, supported by Sofinnova’s Biovelocita II—a €165M biotech acceleration fund dedicated to identifying and developing cutting-edge scientific advancements from top institutes like Gustave Roussy. This effort is undertaken in close collaboration with the institute’s technology transfer office, Gustave Roussy Transfert.
gustave-roussy-sofinnova-bv2-fr-180325.pdf
Press contact
If you are a journalist and have a question, please contact:
Claire Parisel or Léona Pinto
Tel. +33 1 42 11 50 59
Tel. +33 1 42 11 63 59
Mob. +33 6 17 66 00 26
Email
The Media Team cannot respond to patient inquiries.
Last press releases
-
Gold september: two new research programmes launched to tackle childhood cancers
Two of Gustave Roussy’s four new medical and scientific programmes are dedicated to childhood cancers. The first, DECRIPT, aims to improve understanding of the role played by genetics in the development of certain childhood cancers, as well as second cancers that may occur in adulthood. The second, INSPIRE, will draw on the knowledge and techniques already developed at the Institute to create organoids, with the aim of deciphering the mechanisms underlying metastasis and resistance to treatment.
-
Prof. Fabrice Barlesi reappointed at the head of Gustave Roussy, the leading cancer center in France and Europe
By order of Ms. Stéphanie Rist, Minister of Health, Families, Autonomy and Persons with Disabilities, dated 27 July 2026, Professor Fabrice Barlesi has been reappointed as Director General of Gustave Roussy, effective 1 August 2026. At the helm of the Institute for five more years, Prof. Barlesi will continue the transformations undertaken during his first term. This renewal reflects the confidence placed in the project led by the institution to accelerate progress in the fight against cancer, foster and support the development of innovations set to change the future of oncology, and strengthen the influence of one of the world's leading cancer centers.
-
Route du Rhum 2026 Jean Le Cam and Christophe Rateau to sail for Gustave Roussy
For the Route du Rhum - Destination Guadeloupe 2026, Jean Le Cam and Christophe Rateau will sail under the colors of Gustave Roussy, the leading cancer center in France and Europe. Competing respectively in the Vintage and Class40 categories, the two skippers will carry the Institute's mission to the general public, supporting cancer research and raising awareness of prevention, innovation and patient care.
-
Owkin and Gustave Roussy partner to bring K Pro into real-world clinical practice
Owkin and Gustave Roussy, Europe's leading cancer center, today announced a partnership to test K Pro directly within the hospital's real-world clinical and research workflows.
